Invention:
This invention reports the discovery and development of pyrazolopyridine inhibitors that have been shown to be effective in cell culture against multiple strains of non-polio enteroviruses including: EV-D68, EVA71, and CVB3. There are currently no antivirals or vaccines for non-polio enteroviruses, and the health consequences of infection for some can be severe.
Background:
Non-polio enteroviruses are types of viruses that are very common, and more than 100 types exist. Non-polio enteroviruses cause about 10 to 15 million infections in the United States each year. Tens of thousands of people are hospitalized each year for illnesses caused by various non-polio enteroviruses and death can result in some severe cases. Some of these illnesses resulting from non-polio enterovirus pathogens include acute flaccid myelitis (AFM), hand/foot/mouth disease (HFMD), type 1 diabetes, as well as cardiac arrhythmias and heart failure.
Since there are currently no antivirals or vaccines for non-polio enteroviruses, the inventors have developed a method to address this urgent need. In this technology, the inventors have identified pyrazolopyridine-containing small molecules that possess potent and broad-spectrum antiviral activity against non-polio enteroviruses.
Applications:
- Treatment of non-polio enterovirus infections
- Prophylactic prevention from severe disease caused by non-polio enterovirus infections
Advantages:
- Innovative design, utilizes pyrazolopyridine analogs
- Broad-spectrum protection from non-polio enteroviruses
Status: issued U.S. patent #11,834,451
